Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3233/NIB-150101 http://scihub22266oqcxt.onion/10.3233/NIB-150101 26855687/?report=reader!4743661!26855687     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26855687&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Adv+Neuroimmune+Biol 2015 ; 6 (1): 1-8 Nephropedia Template TP {{tp|p=26855687|t=2015. Targeting CXCL13 During Neuroinflammation |pdf=|usr=}}{{26855687}} gab.com Text Targeting CXCL13 During Neuroinflammation JO: Adv Neuroimmune Biol http://www.kidney.de/pget.php?&tw=1&pmid=26855687 #FOAvip The chemokine, C-X-C motif ligand 13 (CXCL13), is constitutively expressed in lymphoid organs and controls the recruitment and compartmentalization of lymphocytes and antigen presenting cells within these specialized structures. Recent data, however, also find induction of this molecule during central nervous system (CNS) inflammation under a variety of circumstances. While its role(s) in the pathogenesis of neoplastic, infectious and autoimmune disorders of the CNS remain incompletely understood, several lines of evidence suggest that CXCL13 could become a relevant therapeutic target in at least some of these diseases. This review focuses on how CXCL13 contributes to the pathogenesis of selected CNS disorders involving both experimental animals and humans, paying particular attention to the issue of whether (and if so, how) blockade of this ligand or its receptor might benefit the host. Current blocking strategies largely involve the use of monoclonal antibodies, but an improved understanding of downstream signaling pathways makes small molecule inhibition a future possibility. Twit Text FOAVip Targeting CXCL13 During Neuroinflammation ????Adv Neuroimmune Biol http://www.kidney.de/pget.php?&tw=1&pmid=26855687 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26855687 #FOAvip English Wikipedia <ref>{{Cite pmid|26855687}}</ref> Targeting CXCL13 During Neuroinflammation #MMPMID26855687 Huber AK; Irani DN Adv Neuroimmune Biol 2015[]; 6 (1): 1-8 PMID26855687show ga The chemokine, C-X-C motif ligand 13 (CXCL13), is constitutively expressed in lymphoid organs and controls the recruitment and compartmentalization of lymphocytes and antigen presenting cells within these specialized structures. Recent data, however, also find induction of this molecule during central nervous system (CNS) inflammation under a variety of circumstances. While its role(s) in the pathogenesis of neoplastic, infectious and autoimmune disorders of the CNS remain incompletely understood, several lines of evidence suggest that CXCL13 could become a relevant therapeutic target in at least some of these diseases. This review focuses on how CXCL13 contributes to the pathogenesis of selected CNS disorders involving both experimental animals and humans, paying particular attention to the issue of whether (and if so, how) blockade of this ligand or its receptor might benefit the host. Current blocking strategies largely involve the use of monoclonal antibodies, but an improved understanding of downstream signaling pathways makes small molecule inhibition a future possibility. äTargeting CXCL13 During Neuroinflammation (epmc).pdf DeepDyve Pubget Overpricing